

Director/PDMR Shareholding

21 July 2021 15:50 BST

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that on 21 July 2021, Marc Dunoyer, Chief Financial Officer, received 21,243 Ordinary Shares of \$0.25 each in the Company (Ordinary Shares). The Ordinary Shares were issued to Mr Dunoyer on completion of the Company's acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part consideration for the 20,000 Alexion shares held by Mr Dunoyer at the time of completion.

In accordance with the Agreement and Plan of Merger entered into by the Company on 12 December 2020, as consideration for each Alexion share held on completion of the acquisition, being 21 July 2021, Alexion shareholders received \$60 in cash and, at their election, either 2.1243 AstraZeneca American Depositary Shares (each representing one half of an Ordinary Share) or the Ordinary Share equivalent.

PDMR	Nature of the transaction	Quantity of Ordinary Shares received	Estimated valuation of price per Ordinary Share
Marc Dunoyer	Ordinary Shares issued in consideration for the acquisition of Alexion Pharmaceuticals, Inc.	21,243	US\$115.08

The attached notification, made in accordance with the requirements of the EU and UK Market Abuse Regulations, gives further detail.

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Marc Dunoyer				
2	Reason for the notification					
a)	Position/status	Chief Financial Officer				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	AstraZeneca PLC				
b)	LEI	PY6ZZQWO2IZFZC3IOL08				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC GB0009895292				
b)	Nature of the transaction	Ordinary Shares issued in consideration for the acquisition of Alexion Pharmaceuticals, Inc.				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)*</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>US\$115.08</td> <td>21,243</td> </tr> </tbody> </table> <p>*non-cash consideration: price is an estimated valuation</p>	Price(s)*	Volume(s)	US\$115.08	21,243
Price(s)*	Volume(s)					
US\$115.08	21,243					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				

e)	Date of the transaction	21 July 2021
f)	Place of the transaction	Outside a trading venue

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca)

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.